You are leaving Lundbeck.com/US
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.
Newsroom
Lundbeck US Newsroom
Here you will find the latest news, stories and insights from Lundbeck US. Lundbeck is a global biopharmaceutical company solely focused on the brain, and our ~1,000 U.S. employees are committed to advancing brain health and transforming lives.
Filter within articles
| Type | Title | Published |
|---|---|---|
| News Release | Lundbeck US Charitable Fund Contributes Nearly $300K to Depression and Bipolar Support Alliance (DBSA) | Mar 3, 2025 |
| News Release | Lundbeck US Charitable Fund Donates $225K to National Headache Foundation’s Operation Brainstorm™ Women in the Military Initiative | Feb 24, 2025 |
| News Release | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA | Feb 12, 2025 |
| News Release | Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies | Jan 30, 2025 |
| News Release | JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults | Dec 18, 2024 |
| Feature | Lundbeck US Charitable Fund Publishes 2023 Impact Report | Dec 11, 2024 |
| News Release | Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline | Oct 14, 2024 |
| News Release | Thomas Gibbs recognized as 2024 PharmaVoice 100 standout leader | Oct 8, 2024 |
| News Release | Barbara Corcoran announces collaboration with Otsuka and Lundbeck to raise awareness of agitation in Alzheimer’s dementia | Sep 26, 2024 |
| News Release | Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2024 | Jul 31, 2024 |
The information in the press releases on these pages are factually acurate on the date of publication. These press releases remain on Lundbeck's website for historical purposes only. Lundbeck assumes no duty to update the information to reflect subsequent developments. Readers should not rely on the information on these pages as current or accurate after their publication dates.
For general media inquiries, contact:
Molly Poarch
Vice President, US Corporate Affairs
Email: MOPC@lundbeck.com
Phone: 224-602-7831
Lundbeck in the US
When it comes to advancing therapies for brain diseases, we stand apart.
Investor relations
Detailed information related to Lundbeck’s financial performance from our Global team.